AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27465740 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for participation
Number of subjects: 76
Study 27465740 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of trial elements
Number of subjects: 76
Study 27465740 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall experience
Number of subjects: 76
Study 27465740 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on clinical outcomes
Number of subjects: 76
Study 23464642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (group 1)
Number of subjects: 30
Study 23464642 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (group 2)
Number of subjects: 30
Study 23464642 — intervention group
Group type: COMPARATOR
Intervention: Both physiotherapy and hydrotherapy (group 3, control group)
Number of subjects: 30
Study 20973770 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with methyl aminolaevulinate
Number of subjects: 0
Study 20973770 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod cream (5%)
Number of subjects: 0
Study 18285373 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal Position (HP)
Number of subjects: 18
Study 18285373 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 degrees head-up tilt Position (TP)
Number of subjects: 18
Study 18285373 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-level Position (3P)
Number of subjects: 18
Study 16503684 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g.kg(‐1) for 7 days)
Number of subjects: 16
Study 16503684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16503684 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 16
Study 12695317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (100-400 mg daily)
Number of subjects: 175
Study 12695317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (0.8-1.1 mEq/L)
Number of subjects: 175
Study 12695317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 10847578 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Timed Get‐up‐and‐Go (ETGUG) test
Number of subjects: 3
Study 10847578 — intervention group
Group type: COMPARATOR
Intervention: Timed Get‐up‐and‐Go (TGUG) test
Number of subjects: 3
Study 9059472 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 13
Study 9059472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 13
Study 9059472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8448257 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and doxapram
Number of subjects: 0
Study 8448257 — intervention group
Group type: COMPARATOR
Intervention: Caffeine and placebo
Number of subjects: 0
Study 2819914 — intervention group
Group type: EXPERIMENTAL
Intervention: brief out‐patient counselling
Number of subjects: 80
Study 2819914 — intervention group
Group type: COMPARATOR
Intervention: general practitioner care
Number of subjects: 80
Study 31930364 — intervention group
Group type: EXPERIMENTAL
Intervention: RimabotulinumtoxinB 2500 U
Number of subjects: 187
Study 31930364 — intervention group
Group type: EXPERIMENTAL
Intervention: RimabotulinumtoxinB 3500 U
Number of subjects: 187
Study 31930364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 30001705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 0
Study 30001705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27567534 — intervention group
Group type: EXPERIMENTAL
Intervention: quantitative cardiotocography (qCTG)
Number of subjects: 720
Study 23721245 — intervention group
Group type: EXPERIMENTAL
Intervention: CP/fosbretabulin (paclitaxel 200 mg/m² followed by carboplatin AUC 6 on day 1 every 3 weeks, with fosbretabulin 60 mg/m² on days 1, 8, and 15)
Number of subjects: 80
Study 23721245 — intervention group
Group type: COMPARATOR
Intervention: CP (paclitaxel 200 mg/m² followed by carboplatin AUC 6 on day 1 every 3 weeks)
Number of subjects: 80
Study 23721245 — intervention group
Group type: EXPERIMENTAL
Intervention: CP/fosbretabulin
Number of subjects: 80
Study 22918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with asthma (AtAs)
Number of subjects: 68
Study 22918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes without asthma (AtNAs)
Number of subjects: 68
Study 22918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-athlete asthmatics (NAtAs)
Number of subjects: 68
Study 22918559 — intervention group
Group type: COMPARATOR
Intervention: Non-athletes (NAtNAs)
Number of subjects: 68
Study 22918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes (both with and without asthma)
Number of subjects: 68
Study 22918559 — intervention group
Group type: COMPARATOR
Intervention: Non-athletes (both with and without asthma)
Number of subjects: 68
Study 21219810 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen + B vitamins
Number of subjects: 56
Study 21219810 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 56
Study 18853551 — intervention group
Group type: EXPERIMENTAL
Intervention: Convex shapes
Number of subjects: 0
Study 18853551 — intervention group
Group type: COMPARATOR
Intervention: Congruent shapes
Number of subjects: 0
Study 18853551 — intervention group
Group type: EXPERIMENTAL
Intervention: Two index fingers (one per surface)
Number of subjects: 0
Study 18853551 — intervention group
Group type: EXPERIMENTAL
Intervention: Opponent shapes
Number of subjects: 0
Study 20878408 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 200 mg IV before the procedure
Number of subjects: 56
Study 20878408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15644641 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mL/kg tidal volume strategy
Number of subjects: 861
Study 15644641 — intervention group
Group type: COMPARATOR
Intervention: 12 mL/kg tidal volume strategy
Number of subjects: 861
Study 15644641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tidal volume strategies
Number of subjects: 861
Study 12111630 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin polysulphate
Number of subjects: 165
Study 12111630 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate
Number of subjects: 165
Study 12111630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 9725631 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty meal at 08.00 h
Number of subjects: 31
Study 9725631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal during the day
Number of subjects: 31
Study 9725631 — intervention group
Group type: COMPARATOR
Intervention: Fasting during the day
Number of subjects: 31
Study 9725631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal at night
Number of subjects: 31
Study 9725631 — intervention group
Group type: COMPARATOR
Intervention: Fasting at night
Number of subjects: 31
Study 7799895 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole treatment (6 month course)
Number of subjects: 20
Study 7799895 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated patients
Number of subjects: 20
Study 7799895 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 healthy fertile women)
Number of subjects: 20
Study 3352195 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin preparation without lidocaine
Number of subjects: 10
Study 3352195 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin preparation with 1% lidocaine
Number of subjects: 10
Study 3352195 — intervention group
Group type: EXPERIMENTAL
Intervention: Excipient formulation without vitamins (isoosmotic)
Number of subjects: 10
Study 3352195 — intervention group
Group type: EXPERIMENTAL
Intervention: Excipient formulation without vitamins (with saline)
Number of subjects: 10
Study 3352195 — intervention group
Group type: COMPARATOR
Intervention: Glycine 2.5% (control)
Number of subjects: 10
Study 29293177 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40
Study 29293177 — intervention group
Group type: COMPARATOR
Intervention: Desflurane/N2O
Number of subjects: 40
Study 27038098 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (2–12 mg/day, once daily at bedtime)
Number of subjects: 0
Study 27038098 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (12 mg)
Number of subjects: 0
Study 27038098 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (not specified dosage)
Number of subjects: 0
Study 25351220 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of sodium hyaluronate
Number of subjects: 48
Study 25351220 — intervention group
Group type: COMPARATOR
Intervention: Disc repair
Number of subjects: 48
Study 23566577 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of intravenous antibiotics (G1)
Number of subjects: 53
Study 23566577 — intervention group
Group type: COMPARATOR
Intervention: 14 days of intravenous antibiotics (G2)
Number of subjects: 53
Study 20458051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant classical cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy
Number of subjects: 2257
Study 20458051 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 2257
Study 17552880 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (500 mg/day)
Number of subjects: 67
Study 17552880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 16644435 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography and NT-proBNP measurements
Number of subjects: 73
Study 16644435 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model based on restrictive filling pattern, NT-proBNP, and peak early diastolic mitral flow to mitral annular E' velocity
Number of subjects: 73
Study 12825916 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct hypnosis with standard medical treatment
Number of subjects: 80
Study 12825916 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect hypnosis with standard medical treatment
Number of subjects: 80
Study 12825916 — intervention group
Group type: COMPARATOR
Intervention: Attention control with standard medical treatment
Number of subjects: 80
Study 12825916 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 80
Study 10661364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0
Study 10661364 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused expressive psychotherapy (FEP)
Number of subjects: 0
Study 10661364 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group members
Number of subjects: 0
Study 10661364 — intervention group
Group type: COMPARATOR
Intervention: Observing group members
Number of subjects: 0
Study 10661364 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional contagion
Number of subjects: 0
Study 8675791 — intervention group
Group type: EXPERIMENTAL
Intervention: High-copper content dental amalgam restorations
Number of subjects: 0
Study 1711250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 50 mg b.i.d.
Number of subjects: 37
Study 1711250 — intervention group
Group type: COMPARATOR
Intervention: Subcapsular orchiectomy
Number of subjects: 37
Study 6355931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasix
Number of subjects: 5
Study 6355931 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurin
Number of subjects: 5
Study 6355931 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusid
Number of subjects: 5
Study 6355931 — intervention group
Group type: COMPARATOR
Intervention: Aqueous solution
Number of subjects: 5
Study 29308939 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (standard treatment plus application of Kinesio Taping on the respiratory muscles)
Number of subjects: 62
Study 27302183 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese girls
Number of subjects: 318
Study 27302183 — intervention group
Group type: COMPARATOR
Intervention: Normal weight girls
Number of subjects: 318
Study 27302183 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese boys
Number of subjects: 318
Study 27302183 — intervention group
Group type: COMPARATOR
Intervention: Normal weight boys
Number of subjects: 318
Study 27302183 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental educational attainment (master or higher)
Number of subjects: 318
Study 27302183 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 318
Study 27302183 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of T1D
Number of subjects: 318
Study 24965569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab 15 mg/kg plus ECX
Number of subjects: 121
Study 24965569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab 7.5 mg/kg plus ECX
Number of subjects: 121
Study 24965569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rilotumumab (both doses) plus ECX
Number of subjects: 121
Study 24965569 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ECX
Number of subjects: 121
Study 22433755 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted Diabetes and Depression Program
Number of subjects: 387
Study 20171420 — intervention group
Group type: EXPERIMENTAL
Intervention: NXN-188 (doses of 2 to 800 mg, 0.027-11.2 mg/kg)
Number of subjects: 203
Study 20171420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 20171420 — intervention group
Group type: EXPERIMENTAL
Intervention: NXN-188
Number of subjects: 203
Study 18400461 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS symptom management manual
Number of subjects: 775
Study 18400461 — intervention group
Group type: COMPARATOR
Intervention: Basic nutrition manual
Number of subjects: 775
Study 16160628 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 62
Study 16160628 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 62
Study 15132403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with simvastatin (10 mg ezetimibe + simvastatin at 10, 20, 40, or 80 mg/d)
Number of subjects: 887
Study 15132403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with simvastatin (10 mg ezetimibe + simvastatin at 10 mg/d)
Number of subjects: 887
Study 15132403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with simvastatin
Number of subjects: 887
Study 15132403 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin monotherapy
Number of subjects: 887
Study 15132403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin and simvastatin monotherapy
Number of subjects: 887
Study 11298622 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF 2.8 microg per kg body-weight
Number of subjects: 16
Study 11298622 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 16
Study 9307639 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized macular hole surgery
Number of subjects: 0
Study 9307639 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 8370566 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort extract (Hypericum), LI 160
Number of subjects: 0
Study 8370566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3723999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of 0.1 ml human diploid cell vaccine (HDCV)
Number of subjects: 44
Study 3723999 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 0.1 ml human diploid cell vaccine (HDCV)
Number of subjects: 44
Study 3723999 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 doses of 0.1 ml human diploid cell vaccine (HDCV)
Number of subjects: 44
Study 3723999 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 doses of 0.1 ml human diploid cell vaccine (HDCV)
Number of subjects: 44
Study 30322724 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-course clindamycin (300 mg twice-daily for 4 days)
Number of subjects: 3105
Study 30322724 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-course clindamycin (300 mg twice-daily for 4 days)
Number of subjects: 3105
Study 30322724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3105
Study 30322724 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-course clindamycin (high-risk subtrial)
Number of subjects: 3105
Study 30322724 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-course clindamycin (high-risk subtrial)
Number of subjects: 3105
Study 30322724 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (combined low-risk groups)
Number of subjects: 3105
Study 27385272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education program with self-help treatment
Number of subjects: 243
Study 27385272 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 243
Study 24602074 — intervention group
Group type: EXPERIMENTAL
Intervention: New gelling fibre dressing containing silver (DURAFIBER™ Ag) for a maximum of 8 weeks
Number of subjects: 14
Study 22391668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (2 mg/kg)
Number of subjects: 34
Study 22391668 — intervention group
Group type: COMPARATOR
Intervention: Control (no infiltration)
Number of subjects: 34
Study 20702747 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape polyphenols (wine grape solid)
Number of subjects: 35
Study 20702747 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape polyphenols (grape seed solids)
Number of subjects: 35
Study 20702747 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study 18188762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (100 microg of purified 3'-aminomethylnicotine conjugated to detoxified Pseudomonas aeruginosa r-exoprotein A)
Number of subjects: 30
Study 18188762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (fourth dose at day 182)
Number of subjects: 30
Study 18188762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15879167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive (OC) users during luteal phase (Lut)
Number of subjects: 23
Study 15879167 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of Oral Contraceptives (NOC)
Number of subjects: 23
Study 15879167 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 23
Study 15879167 — intervention group
Group type: COMPARATOR
Intervention: Oral Contraceptive (OC) users during follicular phase (Fol)
Number of subjects: 23
Study 15879167 — intervention group
Group type: COMPARATOR
Intervention: Cortisol changes with exercise
Number of subjects: 23
Study 12519869 — intervention group
Group type: COMPARATOR
Intervention: Energy availability at 30 kcal/kg LBM.d
Number of subjects: 29
Study 12519869 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy availability below 30 kcal/kg LBM.d
Number of subjects: 29
Study 12519869 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with short luteal phases
Number of subjects: 29
Study 12519869 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy availability on plasma glucose, beta‐hydroxybutyrate, GH, and cortisol
Number of subjects: 29
Study 10202582 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 16
Study 10202582 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 16
Study 7540996 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating dosage of interferon alfa (starting at 3 million units, increasing to 5 million units at 8 weeks for nonresponders, and to 10 million units 8 weeks later for persistent nonresponders)
Number of subjects: 75
Study 7540996 — intervention group
Group type: COMPARATOR
Intervention: Constant dosage of interferon alfa (3 million units three times weekly for 24 weeks)
Number of subjects: 75
Study 2212144 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation A of 2.5% hydrocortisone cream
Number of subjects: 0
Study 2212144 — intervention group
Group type: COMPARATOR
Intervention: Topical formulation B of 2.5% hydrocortisone cream
Number of subjects: 0
Study 648169 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin every other day (5 mg/lb, max 1 gm/day)
Number of subjects: 247
Study 648169 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin twice a week (5 mg/lb, max 1 gm/day)
Number of subjects: 247
Study 31940324 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-viral treatment
Number of subjects: 182
Study 31940324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study 29649833 — intervention group
Group type: EXPERIMENTAL
Intervention: Suctioning MPCNL
Number of subjects: 912
Study 29649833 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL
Number of subjects: 912
Study 29649833 — intervention group
Group type: COMPARATOR
Intervention: Traditional MPCNL
Number of subjects: 912
Study 26766184 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity trail
Number of subjects: 10
Study 26766184 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity trail
Number of subjects: 10
Study 26766184 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity trail
Number of subjects: 10
Study 25543415 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 70
Study 25543415 — intervention group
Group type: COMPARATOR
Intervention: Pseudo‐EA
Number of subjects: 70
Study 22881991 — intervention group
Group type: EXPERIMENTAL
Intervention: Transporters DVD (emotion recognition skills training)
Number of subjects: 55
Study 22881991 — intervention group
Group type: COMPARATOR
Intervention: Thomas the Tank Engine DVD (control)
Number of subjects: 55
Study 20391505 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental knee pain (hypertonic saline injections 0.75 ml)
Number of subjects: 34
Study 20391505 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injections
Number of subjects: 34
Study 20391505 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 34
Study 18774702 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient initiation of home mechanical ventilation (HMV)
Number of subjects: 28